What is medication‑overuse headache?

Medication-Overuse Headache: Definition and Key Characteristics

Medication-overuse headache (MOH) is a chronic headache disorder characterized by headache occurring on ≥15 days per month that develops in patients with a pre-existing primary headache disorder (usually migraine) as a consequence of regular overuse of acute or symptomatic headache medications for more than 3 months 1.

Core Diagnostic Criteria

MOH requires three essential elements to be present:

• Pre-existing primary headache disorder (migraine accounts for approximately two-thirds of all MOH cases) 2
• Headache frequency of ≥15 days per month 2
• Duration of ≥3 months with regular overuse of acute headache medication 1

Medication-Specific Thresholds

The threshold for what constitutes "overuse" varies critically by medication class 1:

• Triptans, ergots, combination analgesics, or opioids: ≥10 days per month
• NSAIDs or acetaminophen: ≥15 days per month
• Any combination of multiple drug classes: ≥10 days per month

This distinction is clinically crucial—patients using triptans twice weekly may already be at risk, while NSAID users have slightly more latitude before crossing the overuse threshold.

Clinical Presentation

The headache phenotype in MOH depends on two factors 3:

1. The underlying primary headache disorder
2. The specific class of overused acute medication

MOH represents a worsening or transformation of the pre-existing headache pattern, not an entirely new headache type. Patients typically experience more frequent headaches with characteristics similar to their baseline primary headache, though often less responsive to treatment.

Epidemiology and Risk Factors

MOH affects approximately 1-2% of the general population 2, 4, but is substantially more common among patients already suffering from headache disorders, particularly chronic migraine.

High-risk factors for developing MOH (in order of relative impact) 5:

1. Headache frequency ≥7 days per month (most significant predictor)
2. Migraine diagnosis
3. Frequent use of anxiolytics, analgesics (including opioids), or sedative-hypnotics
4. History of anxiety or depression, especially combined with musculoskeletal or gastrointestinal symptoms
5. Physical inactivity
6. Sick leave >2 weeks in the past year
7. Self-reported whiplash
8. Tobacco use

Pathophysiology

MOH causes both structural and functional brain changes 6. The American Migraine Prevalence and Prevention Study demonstrated specific transformation risks 6:

• 5 days/month of butalbital use
• 8 days/month of opioid use
• 10 days/month of triptan or combination analgesic use
• 10-15 days/month of NSAID use

Critical Clinical Pitfall

Any use of butalbital or opioids increases the risk of transforming episodic migraine into chronic migraine 6. These medications should be avoided entirely for migraine treatment, as even minimal use accelerates chronification 1.

Relationship to Chronic Migraine

MOH is frequently conflated with chronic migraine in clinical practice 2. Approximately 3% of patients with episodic migraine transform to chronic migraine annually 2, and MOH often mimics or coexists with chronic migraine, making differential diagnosis challenging.

Prevention Through Patient Education

Patient education is the cornerstone of MOH prevention 2, 4. Patients must understand:

• The paradoxical relationship between frequent acute medication use and worsening headaches
• Specific frequency limits for their medications (2 days per week maximum for acute treatment) 6
• The importance of early intervention when headache frequency increases
• That MOH is preventable and reversible with appropriate management

The condition's preventability makes early recognition and patient awareness paramount in clinical practice.